参考文献/References:
[1] Pimienta Gonzalez R,Couto Comba P,Rodriguez Esteban M,et al. Incidence, mortality and positive predictive value of type 1 cardiorenal syndrome in acute coronary syndrome[J]. PLoS One,2016,11(12):e0167166.
[2] Mehta RL,Kellum JA,Shah SV,et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury[J]. Crit Care,2007,11(2):R31.
[3] Kidney Disease.Improving Global Outcomes(KDIGO) Acute Kidney Injury Work Group KDIGO Clinical Practice Guideline for Acute Kidney Injury[J]. Kidney Int,2012,2(suppl 1):1-138.
[4] Rodrigues FB,Bruetto RG,Torres US,et al. Incidence and mortality of acute kidney injury after myocardial infarction:a comparison between KDIGO and RIFLE criteria[J]. PLoS One,2013,8(7):e69998.
[5] Marenzi G,Cosentino N,Bartorelli AL. Acute kidney injury in patients with acute coronary syndromes[J]. Heart,2015,101(22):1778-1785.
[6] Libby P. Mechanisms of acute coronary syndromes and their implications for therapy[J]. N Engl J M ed,2013,368(21):2004-2013.
[7] Fan PC,Chen TH,Lee CC,et al. ADVANCIS score predicts acute kidney injury after percutaneous coronary intervention for acute coronary syndrome[J]. Int J Med S ci,2018,15(5):528-535.
[8] Hering D,Winklewski PJ. Autonomic nervous system in acute kidney injury[J]. Clin Exp P harmacol P hysiol,2017,44(2):162-171.
[9] Pastori S,Virzi GM,Brocca A,et al. Cardiorenal syndrome type 1:a defective regulation of monocyte apoptosis induced by proinflammatory and proapoptotic factors[J]. Cardiorenal Med,2015,5(2):105-115.
[10]Ortega-Hernandez J,Springall R,Sanchez-Munoz F,et al. Acute coronary syndrome and acute kidney injury:role of inflammation in worsening renal function[J]. BMC Cardiovasc D isord,2017,17(1):202.
[11]Lin KY,Shang XL,Guo YS,et al. Association of preprocedural hyperglycemia with contrast-induced acute kidney injury and poor outcomes after emergency percutaneous coronary intervention[J]. Angiology,2018,69(9):770-778.
[12]Fox CS,Muntner P,Chen AY,et al. Short-term outcomes of acute myocardial infarction in patients with acute kidney injury:a report from the national cardiovascular data registry[J]. Circulation,2012,125(3):497-504.
[13]Vandenberghe W,Gevaert S,Kellum JA,et al. Acute kidney injury in cardiorenal syndrome type 1 patients: a systematic review and meta-analysis[J]. Cardiorenal Med,2016,6(2):116-128.
[14]Shacham Y,Leshem-Rubinow E,Steinvil A,et al. Renal impairment according to acute kidney injury network criteria among ST elevation myocardial infarction patients undergoing primary percutaneous intervention:a retrospective observational study[J]. Clin R es C ardiol,2014,103(7):525-532.
[15]Chawla LS,Eggers PW,Star RA,et al. Acute kidney injury and chronic kidney disease as interconnected syndromes[J]. N Engl J Med,2014,371(1):58-66.
[16]Hoste EAJ,Vandenberghe W. Epidemiology of cardiac surgery-associated acute kidney injury[J]. Best Prac Res Clin Anaesthesiol,2017,31(3):299-303.
[17]Padhy M,Kaushik S,Girish MP,et al. Serum neutrophil gelatinase associated lipocalin(NGAL) and cystatin C as early predictors of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention[J]. Clin C him Acta,2014,435:48-52.
[18]Kashani K,Al-Khafaji A,Ardiles T,et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury[J]. Crit Care,2013,17(1):R25.
[19]Levante C,Ferrari F,Manenti C,et al. Routine adoption of TIMP2 and IGFBP7 biomarkers in cardiac surgery for early identification of acute kidney injury[J]. Int J Artif Organs,2017,40(12):714-718.
[20]Schanz M,Shi J,Wasser C,et al. Urinary [TIMP-2]×[IGFBP7] for risk prediction of acute kidney injury in decompensated heart failure[J]. Clin C ardiol,2017,40(7):485-491.
[21]Menzorov MV,Shutov AM,Larionova NV,et al. Prognostic significance of erythropoietin in patients with acute coronary syndrome[J]. Kardiologiia,2016,56(9):15-20.
[22]Celik IE, Kurtul A, Duran M, et al. Elevated serum fibrinogen levels and risk of contrast-induced acute kidney injury in patients undergoing a percutaneous coronary intervention for the treatment of acute coronary syndrome[J]. Coron A rtery Dis,2016,27(1):13-18.
[23]Murat SN,Kurtul A,Yarlioglues M. Impact of serum albumin levels on contrast-induced acute kidney injury in patients with acute coronary syndromes treated with percutaneous coronary intervention[J]. Angiology,2015,66(8):732-737.
[24]Oh HJ,Kim S,Park JT,et al. Baseline chloride levels are associated with the incidence of contrast-associated acute kidney injury[J]. Sci R ep,2017,7(1):17431.
[25]Pancholy MS,Skelding K,Scott T,et al. Effect of access site choice on acute kidney injury after percutaneous coronary intervention[J]. Am J Cardiol,2017,120(12):2141-2145.
[26]Merten GJ,Burgess WP,Gray LV,et al. Prevention of contrast-induced nephropathy with sodium bicarbonate:a randomized controlled trial[J]. JAMA,2004,291(19):2328-2334.
[27]Weisbord SD,Gallagher M,Jneid H,et al. Outcomes after angiography with sodium bicarbonate and acetylcysteine[J]. N Engl J Med,2018,378(7):603-614.
[28]Pistolesi V,Regolisti G,Morabito S,et al. Contrast medium induced acute kidney injury:a narrative review[J]. J N ephrol,2018,31(6):797-812.
[29]Richter SK,Crannage AJ. Evaluation of N-acetylcysteine for the prevention of contrast-induced nephropathy[J]. J C ommunity Hosp Intern M ed P erspect,2015,5(3):27297.
[30]Tropeano F,Leoncini M,Toso A,et al. Impact of rosuvastatin in contrast-induced acute kidney injury in the elderly: Post Hoc Analysis of the PRATO-ACS Trial[J]. J C ardiovasc P harmacol T her,2016,21(2):159-166.
[31]Marenzi G,Cosentino N,Werba JP,et al. A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes[J]. Int J Cardiol,2015,183:47-53.
[32]Kwok CS,Pang CL,Yeong JK,et al. Measures used to treat contrast-induced nephropathy:overview of reviews[J]. Br J Radiol,2013,86(1021):20120272.
[33]Putzu A, Boscolo Berto M, Belletti A, et al. Prevention of contrast-induced acute kidney injury by furosemide with matched hydration in patients undergoing interventional procedures: a systematic review and meta-analysis of randomized trials[J]. JACC Cardiovasc I nterv,2017,10(4):355-363.
[34]Ostermann M,Joannidis M,Pani A,et al. Patient selection and timing of continuous renal replacement therapy[J]. Blood Purif,2016,42(3):224-237.
相似文献/References:
[1]李润土,何泉.光学相干断层成像在急性冠脉综合征介入治疗中的应用[J].心血管病学进展,2019,(6):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
LI Runtu,HE Quan.Application of Optical Coherent Tomography in Interventional Treatment of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(5):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
[2]周小琳 何泉.替格瑞洛在急性冠脉综合征合并慢性肾脏病患者中的应用研究进展[J].心血管病学进展,2019,(5):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
ZHOU Xiaolin,HE Quan.Ticagrelor in Acute Coronary Syndrome with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2019,(5):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
[3]杜梦阳,袁晋青.对比剂诱导的急性肾损伤研究现状[J].心血管病学进展,2019,(8):1087.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.004]
DU Mengyang,YUAN Jinqing.DU Mengyang,YUAN Jinqing[J].Advances in Cardiovascular Diseases,2019,(5):1087.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.004]
[4]吕俊兴 许海燕.急性冠脉综合征危险评分的研究进展[J].心血管病学进展,2019,(9):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
LU Junxing,XU Haiyan.Risk Scores of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(5):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
[5]吕颖 胡思宁 于波 贾海波.斑块侵蚀发病机制的最新研究进展[J].心血管病学进展,2020,(1):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
LU Ying,HU Sining,YU Bo,et al.Pathogenic Mechanisms of Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(5):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
[6]段继坤,林志,杨帆,等.斑块侵蚀引起的急性冠脉综合征的研究新进展[J].心血管病学进展,2020,(3):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
DUAN Jikun,LIN Zhi,YANG Fan,et al.Acute Coronary Syndrome Caused by Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(5):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
[7]陈凯磊 胡闻竹 苏冠华.P2Y12抑制剂与癌症风险的相关性研究进展[J].心血管病学进展,2020,(8):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
CHEN Kailei,HU Wenzhu,SU Guanhua.Advances in Studies on the Correlation between P2Y12 Inhibitors and Cancer Risk[J].Advances in Cardiovascular Diseases,2020,(5):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
[8]肖雨尘 赵仙先 马丽萍.急性冠脉综合征患者提前停服替格瑞洛现象的研究进展[J].心血管病学进展,2020,(11):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
Acute Coronary Syndrome.Premature Ticagrelor Discontinuation in Patients with[J].Advances in Cardiovascular Diseases,2020,(5):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[9]冯洁渊 .中性粒细胞/淋巴细胞比值和血小板/淋巴细胞比值与急性冠脉综合征的关系研究进展[J].心血管病学进展,2020,(12):1276.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.013]
FENG Jieyuan.The Relationship Between Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio and Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2020,(5):1276.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.013]
[10]魏倩 梁岩.高敏心肌肌钙蛋白在急性冠脉综合征患者中的临床应用进展[J].心血管病学进展,2021,(5):396.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.003]